The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.
April 22nd 2024
A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Diagnostic Criteria for Hidradenitis Suppurativa May Overlook Pediatric Patients
November 16th 2022More than a third (42.8%) of pediatric patients with hidradenitis suppurativa did not meet all major diagnostic criteria at the time of diagnosis, particularly due to failure to fulfill the recurrence interval criterion (2 or more lesions within 6 months).
Read More
Social Impact of Hidradenitis Suppurativa Associated With Worse QOL, Mental Health Burden
November 11th 2022Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.
Read More
Dr Jason Ezra Hawkes Reviews Recent Advances, Unmet Needs in Management of Hidradenitis Suppurativa
November 4th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.
Watch
Hidradenitis Suppurativa ED Readmission Linked to Opioid Prescribing, Medicaid Insurance
November 1st 2022Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Read More
Advocate Discusses Misconceptions, Culturally Sensitive Care for Hidradenitis Suppurativa
October 26th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), spoke on common stigmas regarding HS and how clinicians can improve consultation through a culturally sensitive approach.
Watch
Exploring Strategies for Timely Diagnosis, Comprehensive Care in Hidradenitis Suppurativa
October 18th 2022Researchers reviewed clinical features of hidradenitis suppurativa and provided strategies to promote earlier identification, differentiation from common mimickers, and timely referrals for multidisciplinary management.
Read More
Advocate Speaks on Diet, Holistic Care in Hidradenitis Suppurativa
October 13th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), discusses current knowledge on the impact of diet and other holistic care strategies in the management of HS.
Watch
Assessing Surgical Complications in Management of Hidradenitis Suppurativa
October 10th 2022Approximately 1 in 10 patients with hidradenitis suppurativa (HS) experienced complications related to surgery for HS management, in which extensive resection, using skin flaps or skin grafts as a closure method, was associated with a higher incidence of complications.
Read More
Advocate Addresses Unmet Needs in the Management of Hidradenitis Suppurativa
October 7th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed several pressing issues that warrant consideration to improve the care management of HS.
Watch
Advocate Discusses Surgical, Therapeutic Management of Hidradenitis Suppurativa
September 23rd 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), spoke on the surgical and therapeutic interventions she’s had for the management of HS.
Watch
Advocate Details Challenges Faced in Path to Diagnosis for Hidradenitis Suppurativa
September 16th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed the misconceptions she faced from clinicians regarding her clinical symptoms of HS prior to diagnosis.
Watch
Advocate Discusses Physical, Psychological Impact of Hidradenitis Suppurativa
September 9th 2022Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), speaks on the quality of life burden she has experienced during her HS disease journey.
Watch
Advocate Highlights Misconceptions in the Management of Hidradenitis Suppurativa
August 27th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by hidradenitis suppurativa (HS), spoke on misconceptions she’s encountered on her HS disease journey and the importance for physicians to be conscientious of their advice to patients.
Watch
Advocate Speaks on Critical Research Needs in Hidradenitis Suppurativa
August 20th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.
Watch
Real-world Data Confirm Early Efficacy of Anti-IL-17A Inhibitors for Psoriasis
August 17th 2022Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.
Read More
Advocate Speaks on Prior Authorization, Insurance-Related Barriers for HS Treatment
August 13th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), discussed step edits and other barriers to treatment caused by insurance requirements in the management of HS.
Watch
Advocate Addresses Factors Physicians Should Consider in Managing Hidradenitis Suppurativa
August 5th 2022Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.
Watch
Advocate Discusses Her Family's History With Hidradenitis Suppurativa
July 30th 2022The journey to a diagnosis of hidradenitis suppurativa was different for her compared with the path faced by her children, said Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with the disease.
Watch
Risk of Myocardial Infarction Greater Among Patients With Hidradenitis Suppurativa
July 25th 2022An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.
Read More